INmune Bio Ownership
| INMB Stock | USD 7.19 0.48 6.26% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 19.3 M | Current Value 20.2 M | Avarage Shares Outstanding 14.5 M | Quarterly Volatility 3.5 M |
INmune |
INmune Stock Ownership Analysis
About 24.0% of the company shares are held by company insiders. The book value of INmune Bio was currently reported as 1.74. The company recorded a loss per share of 2.18. INmune Bio had not issued any dividends in recent years. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about INmune Bio call the company at 858 964 3720 or check out https://www.inmunebio.com.Besides selling stocks to institutional investors, INmune Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different INmune Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align INmune Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
INmune Bio Quarterly Liabilities And Stockholders Equity |
|
INmune Bio Insider Trades History
About 24.0% of INmune Bio are currently held by insiders. Unlike INmune Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against INmune Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of INmune Bio's insider trades
INmune Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as INmune Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading INmune Bio backward and forwards among themselves. INmune Bio's institutional investor refers to the entity that pools money to purchase INmune Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 136.2 K | Deutsche Bank Ag | 2024-12-31 | 109.8 K | Northern Trust Corp | 2024-12-31 | 106 K | Mccormack Advisors International | 2024-12-31 | 100.8 K | Westside Investment Management, Inc. | 2024-12-31 | 90 K | Appleseed Capital | 2024-12-31 | 83.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 77.5 K | Two Sigma Investments Llc | 2024-12-31 | 66.4 K | Goldman Sachs Group Inc | 2024-12-31 | 63.6 K | Blackrock Inc | 2024-12-31 | 989.6 K | Praetorian Pr Llc | 2024-12-31 | 812.2 K |
INmune Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific INmune Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on INmune Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases INmune Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
INmune Bio Outstanding Bonds
INmune Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. INmune Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most INmune bonds can be classified according to their maturity, which is the date when INmune Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45782BAD64 Corp BondUS45782BAD64 | View | |
| Installed Building Products Corp BondUS45780RAA95 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
INmune Bio Corporate Filings
| 7th of March 2025 Other Reports | ViewVerify | |
8K | 4th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of January 2025 Other Reports | ViewVerify | |
F4 | 9th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.